Troutman Pepper Advises Palvella Therapeutics in Series D Financing
Troutman Pepper client Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company, recently announced the initial closing of its Series D financing of up to $37.7 million.
Source: pennrecord.com